Morgan Stanley lowered the firm’s price target on WW (WW) to $21 from $34.50 and keeps an Equal Weight rating on the shares. A mix shift from behavioral to clinic is happening far faster than the firm anticipated, but this comes with upside as well as “negative trade-offs,” the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WW:
- Novo Nordisk launches multi-month subscription program for Wegovy
- Midday Fly By: Meta said to eye job cuts, Dollar Tree up after earnings
- Morning Movers: National Storage surges following Public Storage buyout
- WW reports Q4 EPS (58c) vs. 31c last year
- WW sees FY26 revenue $620M-$635M, consensus $631.76M